07:58 AM EDT, 03/10/2025 (MT Newswires) -- Ionis Pharmaceuticals ( IONS ) said Monday that the company and partner AstraZeneca's ( AZN ) Wainzua received approval in the European Union to treat hereditary transthyretin-mediated amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy, or ATTRv-PN.

Wainzua was approved for ATTRv-PN treatment in the US in December 2023 and has received approvals in other countries, including the UK and Canada, the company said.

ATTRv-PN results in peripheral nerve damage with motor disability within five years of diagnosis. Without treatment, the disease is "generally fatal" within 10 years, Ionis said.

Shares of Ionis rose 1.4% in recent premarket activity, while AstraZeneca ( AZN ) fell 1.7%.